These data redefine the function of nPD-L1 in tumour, and we speculate that targeting KPNB1 or MerTK signaling pathway in combination with PD-L1 immunotherapy may improve the clinical outcome of NSCLC patients. The gene discussed is MERTK; the disease is non-small cell lung carcinoma.